Assay Development Biophysical Assays Pharmaceuticals 
Sygnature Discovery
JUNE 17, 2024
From hit finding and target engagement studies, to the characterisation of kinetic properties for late-stage candidate molecules, we believe that a biophysical approach complements other assays to deliver a fuller picture of binding behaviour to produce more effective therapeutics.
Drug Target Review
NOVEMBER 1, 2023
We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca.
Expert insights. Personalized for you.
52 
Let's personalize your content